JPRN-UMIN000021959Completed未知
Study of the efficacy and safety of tadalafil and imidafenacin combination therapy for benign prostatic hyperplasia with overactive bladder - Study of the efficacy and safety of tadalafil and imidafenacin combination therapy for benign prostatic hyperplasia with overactive bladder
Kawahara Clinic0 sites30 target enrollmentStarted: April 19, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 50years-old to ot applicable (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who meet any of the following conditions at the first visit are excluded: (1) Residual urine volume of 100 mL or more (2) Suspicion of polyuria (3) Currently have, or have a past history of, urinary retention (4) Qmax of less than 5 mL/s (5) Neoplasm of the lower urinary tract such as prostate or bladder cancer, neurogenic bladder, urethral stricture, chronic bacterial prostatitis, urinary tract infection, urinary tract stone, or interstitial cystitis (6) Contraindication to the prescription of tadalafil or imidafenacin (7) Severe liver dysfunction, kidney dysfunction, or heart disease (8) Pyloric, duodenal, or other intestinal obstruction, decreased gastrointestinal motility or distention, paralytic ileus, closed angle glaucoma, or myasthenia gravis (9) Taking a prohibited concurrent medication within 4 weeks prior to starting the study (5&alpha-reductase inhibitor, sex hormone agent within 6 months) (10) Received a prohibited concurrent therapy within 8 weeks prior to starting the study (11) Change in dose or regimen within 8 weeks prior to starting the study of a concurrent restricted medication or therapy (12) Otherwise, determined to be inappropriate by the doctor
Investigators
Similar Trials
Completed
Phase 2
Efficacy of Tadalafil on Lower Urinary tract Symptoms of patients with ureteral stentsTS associated with ureteral stents.hematuria, dysuria, pain , urgency , frequency, incontinanceR30-39IRCT2013113015597N1Tabriz University of Medical Sciences80
Active, not recruiting
Phase 4
The effect of tadalafil in the treatment of erectile dysfunction in patients with chronic renal failureerectile dysfunctionend stage renal diseasehaemodialysiskidney transplantRenal DialysisKidney TransplantationErectile DysfunctionKidney Failure, ChronicTCTR20220310008rology-Nephrology Research Center of Shahid Beheshti University of Medical Sciences45
Not yet recruiting
Phase 4
A study to compare the beneficial effect and safety of tadalafil compared to sildenafil in pulmonary hypertensive patients due to lung diseaseCTRI/2024/06/069470Midhun Sakravarthy J
Completed
Not Applicable
Effect of Tadalafil in treatment of Overactive bladderoveractive bladder syndrom.Bladder contractedIRCT2013030212668N1Vice-Research of Medical School of Tabriz University of Medical Sciences90
Recruiting
Phase 3
The effect of oral vitamin D on erectile dysfunctioMale erectile dysfunction.Male erectile dysfunctionIRCT20151123025202N34Hamedan University of Medical Sciences122